In the early 1990s, in a clinical trial run out of a Pfizer laboratory in the south of England, a group of male volunteers were testing a new compound meant to treat angina—the crushing chest pain of a heart starved of blood. The molecule, dryly labeled UK-92,480, was supposed to relax the vessels feeding the heart. It barely did. By most measures, the trial was a disappointment. Then the volunteers started reporting an unusual side effect, and a failed heart drug quietly became one of the most consequential accidents in modern medicine.

That compound is now known as sildenafil. Its story is a rare case where serendipity, Nobel-winning biology, and a single small molecule collide—and it explains far more about how the human body works than its reputation suggests.

A heart drug that failed upward

The science started with a reasonable bet. In 1986, Pfizer chemists identified a class of compounds that powerfully blocked an enzyme called phosphodiesterase type 5, or PDE5. The theory was that switching off PDE5 would widen blood vessels and ease angina. UK-92,480 was the most promising candidate, and it went into human trials with the heart in mind.

The heart was unimpressed. The drug cleared the body quickly and did little for chest pain. But trial participants kept noticing something the researchers hadn't been looking for: erections, appearing without the usual context. Rather than bury an inconvenient result, Pfizer's scientists chased it. Follow-up work confirmed that PDE5 was concentrated in the tissue of the penis—far more than in the heart muscle—and the project pivoted entirely. In 1998, sildenafil reached the U.S. market as Viagra, the first pill ever approved to treat erectile dysfunction. A medicine designed for the chest had found its purpose several inches lower.

The Nobel-winning gas hiding inside the pill

Here's the part that turns a quirky anecdote into real science. The very same year sildenafil launched, the 1998 Nobel Prize in Physiology or Medicine went to three pharmacologists—Robert Furchgott, Louis Ignarro, and Ferid Murad—for showing that a humble gas, nitric oxide, acts as a signaling molecule in the cardiovascular system. They had uncovered an entirely new way that cells talk to one another, and it is precisely the conversation sildenafil eavesdrops on.

In plain terms, the chain works like this:

• Arousal releases nitric oxide. Nerves and the lining of blood vessels in the penis puff out tiny amounts of this short-lived gas—a chemical "go" signal.
• Nitric oxide switches on a messenger. It triggers production of a molecule called cGMP, which tells the smooth muscle in vessel walls to relax. Relaxed vessels widen, blood flows in, and an erection follows.
• An enzyme erases the message. PDE5's job is to break cGMP back down and end the signal. In many men with ED, that cleanup happens too fast or the original signal is too weak.
• Sildenafil tells the cleanup crew to wait. By blocking PDE5, the drug lets cGMP linger, so the body's own "relax and fill" instruction lasts long enough to matter.

What sildenafil does not do is generate the original signal. It doesn't manufacture desire or release nitric oxide on its own—it only amplifies a message the body has already started sending. No arousal means no nitric oxide, which means the pill has almost nothing to work with. That single fact, lost in decades of jokes, is why it was never an aphrodisiac.

Why nitrates are the one true red line

The nitric-oxide story also explains the most important safety rule attached to the entire drug class. Decades earlier, Ferid Murad had shown that nitroglycerin—the classic angina remedy—works by flooding the body with nitric oxide. So a man who takes a nitrate is already pressing hard on the body's vasodilation pedal. Add a PDE5 inhibitor, which disables the brakes, and vessels throughout the body can relax all at once, sending blood pressure into a potentially fatal dive. It isn't a coincidence or a quirk; it's the same pathway pushed from two directions at the same time. This is the molecular reason the combination is treated as an absolute contraindication, not a cautious "maybe."

The molecule's many second lives

Because sildenafil's real talent is relaxing blood vessels, its career didn't end with sexual medicine. Researchers turned it back toward the circulatory system it was born to treat—this time successfully. Under the name Revatio, the same molecule became a treatment for pulmonary arterial hypertension, a dangerous rise in blood pressure inside the lungs. It has been studied for high-altitude lung problems in climbers and for Raynaud's phenomenon, where blood flow to the fingers and toes shuts down in the cold. The "failed" heart drug, in other words, eventually circled back and made good on its original promise.

Today that one molecule exists in a sprawling family of products: the original branded pill, its lower-dose lung-disease sibling, and a long list of international generics. A generic sildenafil citrate tablet sold abroad and the famous blue lozenge are, chemically, two expressions of the same Nobel-adjacent biology—though, as with any prescription medicine, formulation, regulation, and oversight vary enormously from one product and country to the next.

What the little pill really teaches

Strip away the marketing and the punchlines, and sildenafil is a near-perfect parable of how medicine actually advances. It came from a wrong guess that produced a right answer. It depended on basic researchers who spent years chasing an invisible gas with no product in mind. And it works not by overpowering the body but by listening to a signal the body already speaks—and simply keeping that signal on the line a little longer.

That's the quiet lesson hiding inside the world's most joked-about pill: the most powerful medicines are often the ones that understand the body's own language well enough to join the conversation.

References

1. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Reviews Drug Discovery, 2006.
2. The Nobel Prize in Physiology or Medicine 1998 (Robert F. Furchgott, Louis J. Ignarro, Ferid Murad). NobelPrize.org.
3. The Science and Practice of Erection Physiology: nitric oxide signaling and PDE5 inhibitors. National Library of Medicine (PMC).
4. Murad F. Nitric oxide and nitrovasodilators: foundational work on the nitric oxide–cGMP pathway, 1977 onward.

This article is for general educational purposes and is not medical advice. Sildenafil is a prescription medicine; always consult a qualified healthcare professional before starting, stopping, or combining any medication.